Loading…
← CockpitCompetitor Analysis › GRDN Guardian Pharmacy Services, Inc. Class AOpen in the cockpit ↗

Guardian Pharmacy Services, Inc. Class AGRDNCompetitor analysis, valuation and peers

United States · USD·Consumer Staples›Drugstore Chains

Institutional pharmacy operator dispensing medications to residents of senior living and long-term care facilities.

Momentum leader 94
Mkt cap
$3.09B
US dollars, full cap
Free float
42%
of shares outstanding
$/day
$22.0M
20-day average traded
Fwd P/E
33.3×
forward earnings
ROIC−WACC
+28.5 pp
WACC 6.6%
Hurdle
-12 pp
Req g minus delivered
Next earnings
133 days
31 Mar 2027
Close · USD$48.84
1D-3.0%
1W-2.3%
1M+16.6%
3M+30.3%
6M+29.8%
YTD+62.3%
1Y+72.4%
ATR %3.9%
Beta0.67
52w lowhigh4.0% off high

What Guardian Pharmacy Services does

Institutional pharmacy operator dispensing medications to residents of senior living and long-term care facilities.

Dispenses medications resident by resident and is paid per prescription, mainly by Medicare Part D drug plans, Medicaid and private payers rather than the facility itself. It operates through a set of local pharmacies, each close to the facilities it serves, and has grown by buying small institutional pharmacies.

Products and services

  • Prescription dispensing for LTC facilities
  • Medication packaging/adherence systems
  • Clinical/consulting pharmacy services

Customers

  • Assisted living/skilled nursing facilities
  • Senior living operators

Where it sits in the supply chain

  • Consumer staples/healthcare
  • Institutional (long-term-care) pharmacy
  • Medication dispensing/packaging for…

What could go right

  • Aging population/senior living growth
  • Facility consolidation into larger pharmacy networks

What could go wrong

  • Reimbursement/regulatory risk
  • Facility customer concentration

Moat: narrow (switching costs, scale, regulatory licence). Facility contracts and integrated dispensing systems are disruptive and costly for operators to switch.

Headquarters: Atlanta, Georgia, US · Employees: 3,600

Named competitors

Guardian Pharmacy Services at a glance

Size Guardian Pharmacy Services (GRDN) is a United States Consumer Staples company (Drugstore Chains) with a market value of $3.09B, the 1517th largest of 3,085 United States companies the cockpit tracks. Shares closed at $48.84 on 18 Nov 2026.

Performance Over six months the shares gained 29.8%, against +10.3% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 11 in its peer set.

Growth Revenue grew 4.8% over the last twelve months (peer median +6.4%); the operating margin is 6.3% (peer median 4.8%).

Valuation It trades at 33.3× forward earnings against a peer median of 16.6× (most expensive of 10).

Price implies For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is -12 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 28.5 points above its cost of capital (6.6% WACC).

Short interest Short interest is 3.5% of the free float (30 Oct 2026).

Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026GRDN 127Peer median 114
Six months, rebased to 100: Guardian Pharmacy Services against the median of its 10 peers (local-currency closes).

Guardian Pharmacy Services financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$1.46B$1.45B$1.23B$1.05B$909M
Revenue growth—+18%+17%+15%—
Gross profit$327M$282M$235M$200M$178M
EBITDA$116M$111M-$43.1M$59.2M$68.6M
Net income$74.8M$49.2M-$110M$23.9M$35.4M
Free cash flow$96.2M$80.7M$41.6M$56.3M$31.8M
Capital expenditure$17.9M$19.5M$16.4M$14.6M$16.8M
Total debt$35.6M$44.7M$37.3M$68.2M$63.0M

Quarterly statements and history in the cockpit →

Guardian Pharmacy Services competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-10%0%+10%+20%+30%0%+5%+10%+15%998976496032336039396038833391314830889627002727GRDN6-month return →1-month return →
Up and to the right = strong over both horizons. Guardian Pharmacy Services is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%20×30×99897649603233339130889627GRDNRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Guardian Pharmacy Services is the large dot.

Capital: growth delivered against growth the price implies

-10%0%+10%-10%0%10%998976496032336038833391314830889627002727GRDNGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Guardian Pharmacy Services is the large dot.

Guardian Pharmacy Services competitors and peer comparison

Head to head with its named competitors (GRDN vs CVS vs BTSG)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Guardian Pharmacy Services GRDN$3.09B+30%+5%6%33.3×4.4%
CVS Health CVS$104B-13%+7%4%9.6×-3.8%
BrightSpring Health Services BTSG$13.6B+17%+23%4%28.8×24.9%

How Guardian Pharmacy Services compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Guardian Pharmacy Services against its 10 peers (data as of 18 Nov 2026)
MeasureGRDNPeer medianRank in peer set
1-month return+16.6%+6.7%highest of 11
6-month return+29.8%+10.3%highest of 11
Distance from 52-week high-4.0%-8.0%3rd highest of 11
Revenue growth (TTM)+4.8%+6.4%4th lowest of 11
Operating margin6.3%4.8%4th highest of 11
Forward P/E33.3×16.6×most expensive of 10
Growth the price implies (Req g, 7 yrs)4.4%-9.2%most demanding of 11
Growth delivered (Del g)+16.8%+10.3%2nd highest of 11
Hurdle (Req g minus delivered)-12.4 pp-20.4 pp2nd most demanding of 11
ROIC minus cost of capital+28.5 pp+7.6 pphighest of 11
EV / EBITDA26.1×7.2×most expensive of 7
Net debt / EBITDA-0.7×-0.3×3rd least indebted of 7

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Guardian Pharmacy Services GRDNUnited States$3.09B+30%+5%6%33.3×4.4%+16.8%
Sundrug 9989.TJapan$3.07B+10%+4%6%14.9×-7.3%+5.8%
Sugi 7649.TJapan$3.46B-9%+9%5%17.9×-9.0%+10.9%
DaShenLin Pharmaceutical 603233.SSChina$3.64B+10%+7%8%15.9×-9.5%+13.6%
Yifeng Pharmacy Chain 603939.SSChina$4.84B+16%+5%10%17.2×-9.3%+13.2%
LBX Pharmacy Chain Joint Stock 603883.SSChina$1.71B+13%+3%5%16.1×-10.7%+9.7%
TSURUHA 3391.TJapan$7.15B+17%+114%4%23.8×-1.5%+9.6%
Create SD 3148.TJapan$1.32B+3%+9%5%n/a-11.5%+8.0%
MatsukiyoCocokara & 3088.TJapan$7.51B+29%+6%8%19.5×-4.8%+15.5%
Ain 9627.TJapan$1.25B+2%+42%4%13.8×-6.5%+16.9%
Yixintang Pharmaceutical 002727.SZChina$1.16B+4%-2%3%16.6×-16.0%+6.5%

Questions

Who are Guardian Pharmacy Services's main competitors?
Named competitors: CVS Health (Omnicare) (CVS), BrightSpring Health Services (BTSG), PharMerica (private or unlisted). The cockpit's measured peer set (industry) also includes Sundrug (9989.T), Sugi (7649.T), DaShenLin Pharmaceutical (603233.SS), Yifeng Pharmacy Chain (603939.SS), LBX Pharmacy Chain Joint Stock (603883.SS), TSURUHA (3391.T).
Is Guardian Pharmacy Services expensive compared with its peers?
On forward p/e it trades at 33.3× against a peer median of 16.6×, most expensive of 10 in its peer set. For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is -12 pp: the price already allows for a slowdown.
How has Guardian Pharmacy Services stock performed?
Over six months to 18 Nov 2026 the shares returned +29.8% against +10.3% for the median peer; over one year +72.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.